FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

6	OMB Number:	3235-0287
E	Estimated average bu	urden
Шr	nours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Welgus Howard G.						2. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ARQT]								all appli Directo	cable)		Own	ner
(Last) (First) (Middle) C/O ARCUTIS BIOTHERAPEUTICS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 04/01/2021								below)		belo		ecily
3027 TOWNSGATE ROAD, SUITE 300 (Street) WESTLAKE VILLAGE CA 91361				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(State)	(Zip)															
1. Title of Security (Instr. 3)			2. Transact Date (Month/Day	on 2A. D Execu		Deemed cution Date,	3. Transaction Code (Instr.					5. Amount of		unt of ies cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	t Be	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Price		Transac (Instr. 3	ction(s)		("	nstr. 4)
Common Stock				04/01/2021				M ⁽¹⁾		390	A	\$1.68	306	208	,676(2)	D		
Common Stock 04/01/20				021	21		M ⁽¹⁾		781	A	\$1.68	1.6806		,457(2)	D			
Common Stock 04/01/20				021	21		M ⁽¹⁾		1,029	A	\$6.5	\$6.522		210,486 ⁽²⁾				
Common Stock 04/0				04/01/2)21			S ⁽¹⁾		1,160	D	\$29.25	544 ⁽⁴⁾ 209		,326 ⁽²⁾	D		
Common Stock				04/01/2	04/01/2021			S ⁽¹⁾		1,040	D	\$29.75	549 ⁽⁵⁾ 208		3,286 ⁽²⁾	D		
Common Stock														24	1,991	I	By Tr	y rust ⁽³⁾
			Table							sposed of s, converti				wned				
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction 3A. Deemed Execution Date Execution Date, or Exercise (Month/Day/Year) if any		4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Expira	e Exer ation C th/Day/		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		De Se (In	8. Price of Derivative Security (Instr. 5) Beneficial Owned Following Reported Transacti (Instr. 4)		Owners Form: Direct (or Indir (I) (Inst	hip D) ect	11. Natur of Indired Beneficia Ownersh (Instr. 4)		

Explanation of Responses:

\$1.6806

\$1,6806

\$6,522

Stock Option

Buy) Stock Option

(Right to

(Right to

(Right to

Buy)

Buy) Stock Option

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

04/01/2021

04/01/2021

04/01/2021

2. Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.

(A) (D)

390

781

1,029

Code

М

3. The securities are held of record by The Welgus Living Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Date

Exercisable

(6)

(6)

(7)

Expiration

03/13/2029

03/13/2029

11/20/2029

Title

Stock

Stock

Stock

- 4. The transaction was executed in multiple trades in prices ranging from \$28.53 to \$29.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 5. The transaction was executed in multiple trades in prices ranging from \$29.60 to \$30.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 6. The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase
- 7. The option vests monthly over a four year period beginning November 20, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

Amount

Shares

390

781

1,029

\$0.00

\$0.00

\$0.00

12,105

25 771

12,947

D

D

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.